These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 31290997)

  • 1. Immune checkpoint inhibitors for hepatocellular carcinoma.
    El Dika I; Khalil DN; Abou-Alfa GK
    Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for hepatocellular carcinoma.
    Zongyi Y; Xiaowu L
    Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
    Choi C; Yoo GS; Cho WK; Park HC
    World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
    Roth GS; Decaens T
    Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy.
    Hage C; Hoves S; Ashoff M; Schandl V; Hört S; Rieder N; Heichinger C; Berrera M; Ries CH; Kiessling F; Pöschinger T
    PLoS One; 2019; 14(7):e0219517. PubMed ID: 31291357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.
    Mohr R; Jost-Brinkmann F; Özdirik B; Lambrecht J; Hammerich L; Loosen SH; Luedde T; Demir M; Tacke F; Roderburg C
    Front Immunol; 2021; 12():652172. PubMed ID: 33859646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.
    Kudo M
    World J Gastroenterol; 2019 Feb; 25(7):789-807. PubMed ID: 30809080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.
    Tagliamonte M; Mauriello A; Cavalluzzo B; Ragone C; Manolio C; Petrizzo A; Buonaguro L
    Cancer Lett; 2020 Mar; 473():25-32. PubMed ID: 31875523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.
    Harding JJ
    Future Oncol; 2018 Sep; 14(22):2293-2302. PubMed ID: 29663837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in Hepatocellular Carcinoma.
    Fulgenzi CAM; Talbot T; Murray SM; Silletta M; Vincenzi B; Cortellini A; Pinato DJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):87. PubMed ID: 34424422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma.
    Montella L; Sarno F; Ambrosino A; Facchini S; D'Antò M; Laterza MM; Fasano M; Quarata E; Ranucci RAN; Altucci L; Berretta M; Facchini G
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
    Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
    J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
    Harding JJ; El Dika I; Abou-Alfa GK
    Cancer; 2016 Feb; 122(3):367-77. PubMed ID: 26540029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current status and future of targeted-immune combination for hepatocellular carcinoma.
    Hao L; Li S; Ye F; Wang H; Zhong Y; Zhang X; Hu X; Huang X
    Front Immunol; 2024; 15():1418965. PubMed ID: 39161764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.